Efficacy and Safety of VisuEvo® and Cationorm® for the Treatment of Evaporative and Non-Evaporative Dry Eye Disease: A Multicenter, Double-Blind, Cross-Over, Randomized Clinical Trial
| العنوان: | Efficacy and Safety of VisuEvo® and Cationorm® for the Treatment of Evaporative and Non-Evaporative Dry Eye Disease: A Multicenter, Double-Blind, Cross-Over, Randomized Clinical Trial |
|---|---|
| المؤلفون: | Anna Caretti, Chiara Quisisana, Luca Rossetti, Michele Dei Cas, Ettore Melardi, Daniele Marchina, Paolo Fogagnolo |
| المصدر: | Clinical Ophthalmology (Auckland, N.Z.) |
| بيانات النشر: | Dove, 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Cross over, medicine.medical_specialty, ocular surface, business.industry, Ocular Surface Disease Index questionnaire, Significant difference, Glaucoma, medicine.disease, law.invention, tear break-up time, Double blind, Ophthalmology, Patient satisfaction, glaucoma, Blurred vision, Randomized controlled trial, law, medicine, medicine.symptom, business, meibomian gland disturbance, Ocular surface, evaporative dry eye disease, Original Research |
| الوصف: | Purpose To compare the efficacy of the new lubricating product VisuEvo® (VSE) vs Cationorm® (CTN) in patients with dry eye disease (DED). Methods Seventy-two patients with evaporative (n=54) and non-evaporative DED (n=18) were included in a multicenter, double-blind, 12-week cross-over study to receive VSE (6 weeks) and CTN (6 weeks) in randomized sequence. After baseline, two visits were performed during each period (intermediate and final visit, respectively at 2 and 6 weeks from the beginning of each period). Primary (tear break-up time, TBUT) and secondary endpoints (Schirmer I, Ferning, blink rate, osmometry, cytokine and lipid expression, ocular surface staining, patient satisfaction, and OSDI score) were compared. Results Sixty-three patients were evaluated for efficacy and 68 patients for safety. The intergroup differences for mean TBUT values were not significant at any study visit (baseline 3.2 ±1.5 sec; intermediate visits 4.5 ± 1.9 and 4.5 ± 1.8 sec in VSE and CTN groups, respectively, p = 0.10; final visits 5.4 ± 2.4 and 6.0 ± 3.1, respectively, p=0.63). Also, the assessment of secondary endpoints showed no significant difference between the two groups. The two study treatments were equally effective in evaporative and non-evaporative DED. The safety profile was excellent for both ocular treatments; transient blurred vision was observed in 11 patients only during CTN, 10 patients only during VSE, and 16 during both treatments. Conclusion VSE was non-inferior to CTN in restoring tear film composition, increasing its stability and reducing ocular surface damage in evaporative and non-evaporative DED patients. Study identifier NCT03833882. |
| اللغة: | English |
| تدمد: | 1177-5483 1177-5467 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::368f5d301e1af24629eba3327ab2e2e0 http://europepmc.org/articles/PMC7308118 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....368f5d301e1af24629eba3327ab2e2e0 |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.doi.dedup.....368f5d301e1af24629eba3327ab2e2e0 870 3 unknown 869.682861328125 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....368f5d301e1af24629eba3327ab2e2e0&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
Array ( [0] => Array ( [Url] => https://explore.openaire.eu/search/publication?articleId=doi_dedup___::368f5d301e1af24629eba3327ab2e2e0# [Name] => EDS - OpenAIRE [Category] => fullText [Text] => View record in OpenAIRE [MouseOverText] => View record in OpenAIRE ) ) |
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Efficacy and Safety of VisuEvo® and Cationorm® for the Treatment of Evaporative and Non-Evaporative Dry Eye Disease: A Multicenter, Double-Blind, Cross-Over, Randomized Clinical Trial
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Anna+Caretti%22">Anna Caretti</searchLink><br /><searchLink fieldCode="AR" term="%22Chiara+Quisisana%22">Chiara Quisisana</searchLink><br /><searchLink fieldCode="AR" term="%22Luca+Rossetti%22">Luca Rossetti</searchLink><br /><searchLink fieldCode="AR" term="%22Michele+Dei+Cas%22">Michele Dei Cas</searchLink><br /><searchLink fieldCode="AR" term="%22Ettore+Melardi%22">Ettore Melardi</searchLink><br /><searchLink fieldCode="AR" term="%22Daniele+Marchina%22">Daniele Marchina</searchLink><br /><searchLink fieldCode="AR" term="%22Paolo+Fogagnolo%22">Paolo Fogagnolo</searchLink> ) Array ( [Name] => TitleSource [Label] => Source [Group] => Src [Data] => Clinical Ophthalmology (Auckland, N.Z.) ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => Dove, 2020. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2020 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Cross+over%22">Cross over</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Emedical%5Fspecialty%22">medicine.medical_specialty</searchLink><br /><searchLink fieldCode="DE" term="%22ocular+surface%22">ocular surface</searchLink><br /><searchLink fieldCode="DE" term="%22business%2Eindustry%22">business.industry</searchLink><br /><searchLink fieldCode="DE" term="%22Ocular+Surface+Disease+Index+questionnaire%22">Ocular Surface Disease Index questionnaire</searchLink><br /><searchLink fieldCode="DE" term="%22Significant+difference%22">Significant difference</searchLink><br /><searchLink fieldCode="DE" term="%22Glaucoma%22">Glaucoma</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Edisease%22">medicine.disease</searchLink><br /><searchLink fieldCode="DE" term="%22law%2Einvention%22">law.invention</searchLink><br /><searchLink fieldCode="DE" term="%22tear+break-up+time%22">tear break-up time</searchLink><br /><searchLink fieldCode="DE" term="%22Double+blind%22">Double blind</searchLink><br /><searchLink fieldCode="DE" term="%22Ophthalmology%22">Ophthalmology</searchLink><br /><searchLink fieldCode="DE" term="%22Patient+satisfaction%22">Patient satisfaction</searchLink><br /><searchLink fieldCode="DE" term="%22glaucoma%22">glaucoma</searchLink><br /><searchLink fieldCode="DE" term="%22Blurred+vision%22">Blurred vision</searchLink><br /><searchLink fieldCode="DE" term="%22Randomized+controlled+trial%22">Randomized controlled trial</searchLink><br /><searchLink fieldCode="DE" term="%22law%22">law</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%22">medicine</searchLink><br /><searchLink fieldCode="DE" term="%22medicine%2Esymptom%22">medicine.symptom</searchLink><br /><searchLink fieldCode="DE" term="%22business%22">business</searchLink><br /><searchLink fieldCode="DE" term="%22meibomian+gland+disturbance%22">meibomian gland disturbance</searchLink><br /><searchLink fieldCode="DE" term="%22Ocular+surface%22">Ocular surface</searchLink><br /><searchLink fieldCode="DE" term="%22evaporative+dry+eye+disease%22">evaporative dry eye disease</searchLink><br /><searchLink fieldCode="DE" term="%22Original+Research%22">Original Research</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => Purpose To compare the efficacy of the new lubricating product VisuEvo® (VSE) vs Cationorm® (CTN) in patients with dry eye disease (DED). Methods Seventy-two patients with evaporative (n=54) and non-evaporative DED (n=18) were included in a multicenter, double-blind, 12-week cross-over study to receive VSE (6 weeks) and CTN (6 weeks) in randomized sequence. After baseline, two visits were performed during each period (intermediate and final visit, respectively at 2 and 6 weeks from the beginning of each period). Primary (tear break-up time, TBUT) and secondary endpoints (Schirmer I, Ferning, blink rate, osmometry, cytokine and lipid expression, ocular surface staining, patient satisfaction, and OSDI score) were compared. Results Sixty-three patients were evaluated for efficacy and 68 patients for safety. The intergroup differences for mean TBUT values were not significant at any study visit (baseline 3.2 ±1.5 sec; intermediate visits 4.5 ± 1.9 and 4.5 ± 1.8 sec in VSE and CTN groups, respectively, p = 0.10; final visits 5.4 ± 2.4 and 6.0 ± 3.1, respectively, p=0.63). Also, the assessment of secondary endpoints showed no significant difference between the two groups. The two study treatments were equally effective in evaporative and non-evaporative DED. The safety profile was excellent for both ocular treatments; transient blurred vision was observed in 11 patients only during CTN, 10 patients only during VSE, and 16 during both treatments. Conclusion VSE was non-inferior to CTN in restoring tear film composition, increasing its stability and reducing ocular surface damage in evaporative and non-evaporative DED patients. Study identifier NCT03833882. ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => ISSN [Label] => ISSN [Group] => ISSN [Data] => 1177-5483<br />1177-5467 ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=doi_dedup___::368f5d301e1af24629eba3327ab2e2e0" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=doi_dedup___::368f5d301e1af24629eba3327ab2e2e0</link><br /><link linkTarget="URL" linkTerm="http://europepmc.org/articles/PMC7308118" linkWindow="_blank">http://europepmc.org/articles/PMC7308118</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.doi.dedup.....368f5d301e1af24629eba3327ab2e2e0 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[PhysicalDescription] => Array
(
[Pagination] => Array
(
[PageCount] => 13
[StartPage] => 1651
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Cross over
[Type] => general
)
[1] => Array
(
[SubjectFull] => medicine.medical_specialty
[Type] => general
)
[2] => Array
(
[SubjectFull] => ocular surface
[Type] => general
)
[3] => Array
(
[SubjectFull] => business.industry
[Type] => general
)
[4] => Array
(
[SubjectFull] => Ocular Surface Disease Index questionnaire
[Type] => general
)
[5] => Array
(
[SubjectFull] => Significant difference
[Type] => general
)
[6] => Array
(
[SubjectFull] => Glaucoma
[Type] => general
)
[7] => Array
(
[SubjectFull] => medicine.disease
[Type] => general
)
[8] => Array
(
[SubjectFull] => law.invention
[Type] => general
)
[9] => Array
(
[SubjectFull] => tear break-up time
[Type] => general
)
[10] => Array
(
[SubjectFull] => Double blind
[Type] => general
)
[11] => Array
(
[SubjectFull] => Ophthalmology
[Type] => general
)
[12] => Array
(
[SubjectFull] => Patient satisfaction
[Type] => general
)
[13] => Array
(
[SubjectFull] => glaucoma
[Type] => general
)
[14] => Array
(
[SubjectFull] => Blurred vision
[Type] => general
)
[15] => Array
(
[SubjectFull] => Randomized controlled trial
[Type] => general
)
[16] => Array
(
[SubjectFull] => law
[Type] => general
)
[17] => Array
(
[SubjectFull] => medicine
[Type] => general
)
[18] => Array
(
[SubjectFull] => medicine.symptom
[Type] => general
)
[19] => Array
(
[SubjectFull] => business
[Type] => general
)
[20] => Array
(
[SubjectFull] => meibomian gland disturbance
[Type] => general
)
[21] => Array
(
[SubjectFull] => Ocular surface
[Type] => general
)
[22] => Array
(
[SubjectFull] => evaporative dry eye disease
[Type] => general
)
[23] => Array
(
[SubjectFull] => Original Research
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Efficacy and Safety of VisuEvo® and Cationorm® for the Treatment of Evaporative and Non-Evaporative Dry Eye Disease: A Multicenter, Double-Blind, Cross-Over, Randomized Clinical Trial
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Anna Caretti
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Chiara Quisisana
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Luca Rossetti
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Michele Dei Cas
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Ettore Melardi
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Daniele Marchina
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Paolo Fogagnolo
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 01
[M] => 06
[Type] => published
[Y] => 2020
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-print
[Value] => 11775483
)
[1] => Array
(
[Type] => issn-print
[Value] => 11775467
)
[2] => Array
(
[Type] => issn-locals
[Value] => edsair
)
[3] => Array
(
[Type] => issn-locals
[Value] => edsairFT
)
)
[Numbering] => Array
(
[0] => Array
(
[Type] => volume
[Value] => 14
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Clinical Ophthalmology (Auckland, N.Z.)
[Type] => main
)
)
)
)
)
)
)
|
| IllustrationInfo |